Table 4. Clinical events during long-term follow-up (n = 1,289, 58 ± 41 months).
| Homocysteine level | < 12.0 µmol/L | ≥ 12.0 µmol/L | P value |
|---|---|---|---|
| Number of patients | 876 | 413 | |
| Overall mortality, n (%) | 56 (6.4) | 50 (12.1) | 0.001 |
| Cardiac, n (%) | 30 (3.4) | 33 (8.0) | 0.001 |
| Non-cardiac, n (%) | 26 (3.0) | 17 (4.1) | 0.318 |
| Non-fatal MI, n (%) | 31 (3.5) | 18 (3.8) | 0.450 |
| Target lesion revascularization, n (%) | 87 (9.9) | 46 (11.2) | 0.494 |
| New lesion stenting, n (%) | 83 (9.5) | 56 (13.6) | 0.034 |
| Coronary bypass surgery, n (%) | 15 (1.7) | 9 (2.2) | 0.659 |
| Non-fatal stroke, n (%) | 19 (2.2) | 9 (2.2) | 1.00 |
| MACE, n (%) | 224 (25.6) | 137 (33.3) | 0.005 |
MACE: major adverse cardiac events; MI: myocardial infarction